Compassionate Use of Reslizumab in a Life-threatening Asthma Exacerbation

• Published in: Journal of investigational allergology & clinical immunology Vol. 34; no. 1; pp. 60 - 61
• Main Authors: Granda, P, Villamañán, E, Heinz, S, Laorden, D, Romero, D, Añón, J M, Carpio, C, Sobrino, C, Collada, V, Domínguez-Ortega, J, Herrero, A, Quirce, S, Álvarez-Sala, R
• Format: Journal Article
• Language: English
• Published: Spain Esmon Publicidad 01.01.2024
• Subjects: Asthma; Bronchospasm; Clinical trials; Eosinophilia; Mechanical ventilation; Monoclonal antibodies; Patients; Respiratory function; Severe acute respiratory syndrome coronavirus 2; Critical care; Severe asthma; Reslizumab
• ISSN: 1018-9068; 1698-0808
• DOI: 10.18176/jiaci.0920

Granda et al present a case report of a 36-year-old man with severe asthma exacerbation. The patient had a history of poorly controlled asthma and had been admitted to the hospital multiple times. Despite aggressive therapy, his asthma control did not improve, and he experienced bronchospasm related to SARS-CoV-2 infection. The patient was eventually admitted to the ICU and required mechanical ventilation. Due to the patient's poor clinical course and elevated eosinophilia, compassionate use of reslizumab was recommended. Following the administration of reslizumab, the patient's respiratory parameters improved, and he was successfully weaned off mechanical ventilation. However, he experienced a transient worsening of respiratory function after withdrawal of extracorporeal membrane oxygenation. The potential benefits of anti-IL5 monoclonal antibodies in severe asthma exacerbations have been reported in previous cases. Further randomized clinical trials are needed to determine the clinical significance of these effects.